Trial Profile
A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ReAct; ReAlise
- Sponsors Abbott Laboratories
- 25 Aug 2011 Primary endpoints added as reported by ClinicalTrials.gov.
- 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2009 Trial phase changed from III to IV, actual number of patient (3440) added, additional trial locations identified as reported by ClinicalTrials.gov.